CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the German Patent Office has upheld the “Kreutzer-Limmer I” ’235 (DE 10066235) patent in oral proceedings held before the Opposition Board. The patent was upheld in an amended form and the opponents’ request to revoke the patent was rejected. The ’235 patent stems from the broader Kreutzer-Limmer I patent family, which is exclusively owned by Alnylam, and in this particular case includes broad claims covering methods of silencing disease genes with vector-expressed small interfering RNAs, or “siRNAs,” the molecules that mediate RNAi.
